NCT04189445: Futibatinib in Patients With Specific FGFR Aberrations

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: FGFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients with tumors that express an FGFR mutation are eligible for cohort A
Exclusions: Patients that have not received at least 2 prior systemic regimens for advanced/metastatic disease; Patients with prior treatment of an FGFR inhibitor; Patients with unstable, symptomatic, uncontrolled brain metastases- see trial for details

Comments are closed.

Up ↑